Empowering the next generation of tech leaders! CSL was proud to participate in the Mark Cuban AI Bootcamp. This event offers Philadelphia teens hands-on experience in AI and data innovation. Learn more about our early talent initiatives: https://bit.ly/4gke2qz #PromisingFutures #CSL
CSL's 2025 Half Year Financial Results Webcast
Webcast will be live from 11am on Tuesday, 11th February 2025 (AEDT)
To learn about new gene therapy data in Hemophilia B Click here → | Would you like to read our 2024 Annual Report? Click here to view or download the Annual Report →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: CSL employees in Melbourne, Australia
29 Jan
28 Jan
🐍Snake safety 🐍We’re proud to partner with the University of Queensland and the Australian Reptile Academy on a new project aimed at mapping and improving Human-Snake co-existence in Australia. Funding from #CSLSeqirus will help the project team shed light on human-snake interactions, pave the way for effective interventions, and provide essential snake education to remote communities in Queensland. https://bit.ly/3CtlnpK #CSL #CSLSeqirus #DrivenByOurPromise #Australia #Snakes #Antivenoms #BitesAndStings
28 Jan
Our first approved homegrown recombinant monoclonal antibody represents a significant step forward in the care of HAE. With over 40 years of supporting the HAE community, this approval is reflection of our ongoing commitment to improving the lives of people living with this condition. Read more: https://bit.ly/4awYH4o. #CSL
24 Jan
Behind every breakthrough is the strength of a patient who inspires us. Your resilience drives our mission to innovate and deliver therapies that truly transform lives. #PatientsFirst https://bit.ly/4hp9eks
23 Jan
We are proud to announce that Australia’s Therapeutic Goods Administration \(TGA\) has approved the first and only once-monthly treatment targeting factor XIIa to prevent attacks of #HereditaryAngioedema . This approval will offer HAE patients in Australia an accessible and convenient treatment option to help manage this debilitating condition. Read more: https://bit.ly/4ggOWIW #CSL
23 Jan
Making clinical trials more bear-able! 🐻 Check out why CSL decided to be the first ever to provide these innovative teddy bears to young participants in a clinical trial for hereditary angioedema. https://bit.ly/40pZgZb #CSL
16 Jan
Patient focus. Innovation. Integrity. Collaboration. Superior performance. These aren’t just words – they’re the foundation of everything we do at CSL. Together, we’re shaping the future of health care. #OurValues https://bit.ly/4hiYAM0
9 Jan
Everything is better together. Dave Ross, #CSLSeqirus General Manager, and Chris Larkins, Head of Global Operations were part of a CSL delegation that recently met with Meiji Seika Pharma, our COVID-19 vaccine distribution partner in Japan. #CSLSeqirus #Collaboration #PublicHealth #Innovation #COVID19 #Vaccines #DrivenByOurPromise
